Olanzapine: Uses, Dosage, How it Works
Class:
Atypical Antipsychotics
Medicine Details
Pharmaceutical Name:
Olanzapine
Dosage:
Adults; titrate slowly, often bedtime; lower in elderly/hepatic impairment: Schizophrenia: Start 5–10 mg once daily, target 10–20 mg/day Bipolar I (mania/mixed): Start 10–15 mg once daily, range 5–20 mg/day
Administration:
Oral tablet or orally disintegrating tablet (Zydis) once daily, with or without food. Short-acting IM (acute agitation) and long-acting injectable (Relprevv) also available.
Drug Alternatives:
Quetiapine (Seroquel), Risperidone, Aripiprazole (Abilify), Lurasidone (Latuda), Cariprazine (Vraylar).
Manufacturer:
Oral tablet or orally disintegrating tablet (Zydis) once daily, with or without food. Short-acting IM (acute agitation) and long-acting injectable (Relprevv) also available.
What Is Olanzapine?
Olanzapine is a prescription medication belonging to the atypical antipsychotic class of drugs. It functions by aiding the restoration of equilibrium among specific brain chemicals, notably dopamine and serotonin. Doctors primarily prescribe it to treat schizophrenia and bipolar disorder, though it has several other approved and off-label uses.
Unlike older “typical” antipsychotics, olanzapine was designed to cause fewer movement-related side effects while still effectively managing symptoms of psychosis and mood disorders.
How Olanzapine Works
Olanzapine affects multiple neurotransmitter receptors in the brain:
- Dopamine D2 receptors: Reduces hallucinations, delusions, and disorganized thinking
- Serotonin 5-HT2A receptors: Improves mood, sleep, and reduces negative symptoms
- Muscarinic acetylcholine receptors: Contributes to some side effects like dry mouth
- Histamine H1 receptors: Causes sedation and increased appetite
- Alpha-1 adrenergic receptors: May cause dizziness upon standing
This broad receptor profile explains why olanzapine is effective for various symptoms but also why it produces diverse side effects.
What Is Olanzapine Used For?
Schizophrenia
Olanzapine treats both positive symptoms (hallucinations, delusions) and negative symptoms (social withdrawal, lack of motivation) of schizophrenia. It’s approved for adults and adolescents aged 13-17.
Bipolar Disorder
- Acute manic or mixed episodes: Administered as monotherapy or combined with lithium or valproate.
- Maintenance treatment: Prevents recurrence of manic, depressive, or mixed episodes
- Approved for adults and adolescents aged 13-17 for manic/mixed episodes
Treatment-Resistant Depression
When combined with fluoxetine (brand name Symbyax), olanzapine treats:
- Depressive episodes associated with bipolar disorder
- Treatment-resistant depression in adults
Off-Label Uses (Not FDA-Approved But Sometimes Prescribed)
- Severe anxiety disorders
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
- Eating disorders (particularly anorexia nervosa)
- Chemotherapy-induced nausea and vomiting
- Agitation in dementia (with caution due to stroke risk)
- Insomnia (low doses, though controversial)
- Borderline personality disorder
Olanzapine Dosage and Administration
Standard Dosage Ranges
| Condition | Starting Dose | Usual Range | Maximum |
|---|---|---|---|
| Schizophrenia (adults) | 5-10 mg daily | 10-20 mg daily | 20 mg daily |
| Bipolar mania (adults) | 10-15 mg daily | 5-20 mg daily | 20 mg daily |
| Bipolar maintenance | 5-20 mg daily | 5-20 mg daily | 20 mg daily |
| Depression with fluoxetine | 5 mg daily | 5-12.5 mg daily | 18 mg olanzapine/75 mg fluoxetine |
| Schizophrenia (adolescents) | 2.5-5 mg daily | 10-20 mg daily | 20 mg daily |
Administration Tips
- Take once daily, with or without food
- Evening dosing often preferred due to sedating effects
- Tablets should be swallowed whole; orally disintegrating tablets dissolve on tongue
- Injectable long-acting form (Zyprexa Relprevv) given every 2-4 weeks by healthcare provider
- Never stop suddenly without medical supervision
Complete Drug Specifications Table
| Specification | Details |
|---|---|
| Generic Name | Olanzapine |
| Brand Names | Zyprexa, Zyprexa Zydis (orally disintegrating), Zyprexa Relprevv (long-acting injectable), Symbyax (with fluoxetine) |
| Drug Class | Atypical antipsychotic, second-generation antipsychotic, thienobenzodiazepine derivative |
| FDA Approval | 1996 (United States) |
| Manufacturer | Eli Lilly and Company (original), multiple generic manufacturers |
| Available Forms | Oral tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg), orally disintegrating tablets, intramuscular injection, powder for injection |
| Half-life | 21-54 hours (average 30 hours) |
| Time to Peak | 5-8 hours (oral); 15-45 minutes (intramuscular) |
| Protein Binding | 93% bound to plasma proteins |
| Metabolism | Liver (CYP1A2 primarily, also CYP2D6) |
| Excretion | Urine (57%) and feces (30%) |
| Pregnancy Category | C (risk cannot be ruled out) |
| Controlled Substance | No |
| Storage | Room temperature (20-25°C/68-77°F), protect from light and moisture |
Olanzapine Side Effects
Very Common Side Effects (Affecting More Than 10% of Users)
| Side Effect | Description | Management |
|---|---|---|
| Weight gain | Average 5-10 kg (11-22 lbs) in first year | Diet, exercise, regular monitoring; may require medication change |
| Sedation/drowsiness | Feeling sleepy, fatigue | Take at bedtime; usually improves over time |
| Dry mouth | Reduced saliva production | Sugar-free gum, frequent water sips, good oral hygiene |
| Constipation | Difficult bowel movements | High-fiber diet, hydration, exercise; laxatives if needed |
| Increased appetite | Strong hunger, cravings | Meal planning, healthy snacks, behavioral strategies |
| Dizziness | Lightheadedness, especially when standing | Rise slowly from sitting/lying positions |
| Metabolic changes | Elevated blood sugar, cholesterol | Regular blood tests, lifestyle modifications |
Serious Side Effects (Require Immediate Medical Attention)
- Metabolic Syndrome and Diabetes. Olanzapine can cause high blood sugar, sometimes leading to diabetic ketoacidosis or coma. Warning signs include excessive thirst, frequent urination, fruity breath, or confusion.
- Neuroleptic Malignant Syndrome (NMS). A rare but life-threatening reaction with symptoms: high fever, muscle rigidity, confusion, irregular heartbeat, and blood pressure changes.
- Tardive Dyskinesia. Involuntary repetitive movements, often of the face (lip smacking, tongue movements). May be permanent even after stopping the drug.
- Stroke and Death in Elderly Dementia Patients. Increased risk in elderly patients with dementia-related psychosis—olanzapine is not approved for this use.
- Seizures. Lowered seizure threshold, particularly in those with epilepsy.
- Blood Disorders. Rarely causes low white blood cell count (agranulocytosis), increasing infection risk.
- Liver Problems. Elevated liver enzymes; rare severe liver injury.
- Priapism. Prolonged, painful erection requiring emergency treatment.
Important Warnings and Precautions
Black Box Warnings (Most Serious FDA Alerts)
- Increased mortality in elderly patients with dementia-related psychosis
- Olanzapine is not approved for treating dementia-related psychosis
- Older adults with dementia face a heightened mortality risk when using antipsychotic medications.
- Metabolic changes
- Risk of hyperglycemia, diabetes, dyslipidemia, and weight gain
- Requires regular monitoring of weight, blood sugar, and lipids
Other Critical Precautions
- Suicide risk: Typically young adults may be at risk of experiencing suicidal thoughts while using antidepressants.
- Orthostatic hypotension: Sudden blood pressure drops when standing
- Cognitive and motor impairment: Avoid driving until you know how the drug affects you
- Body temperature regulation: Avoid overheating and dehydration
- Aspiration pneumonia: Risk increased in patients with swallowing difficulties
Olanzapine and Drug Interactions
Medications That Increase Olanzapine Levels (Risk of Toxicity)
| Drug Type | Examples | Effect |
|---|---|---|
| CYP1A2 inhibitors | Fluvoxamine, ciprofloxacin | May double olanzapine levels |
| CYP2D6 inhibitors | Fluoxetine, paroxetine | Moderate increase in levels |
| Benzodiazepines | Diazepam | Additive sedation |
Medications That Decrease Olanzapine Levels (Reduced Effectiveness)
| Drug Type | Examples | Effect |
|---|---|---|
| CYP1A2 inducers | Carbamazepine, rifampin, smoking | May reduce levels by 50% |
| Charcoal | Activated charcoal | Reduces absorption |
Other Important Interactions
- Blood pressure medications: Additive hypotensive effects
- Anticholinergic drugs: Increased confusion, constipation, urinary retention
- Levodopa and dopamine agonists: Olanzapine may reduce their effectiveness
- Alcohol: Increased sedation and impairment (avoid completely)
Special Populations
Pregnancy
- Category C: Animal studies show adverse effects; human studies limited
- Risk of withdrawal symptoms or extrapyramidal symptoms in newborns if used in third trimester
- Discuss risks versus benefits with doctor; untreated psychiatric illness also carries risks
Breastfeeding
- Excreted in breast milk
- Infants may experience sedation, difficulty feeding, or developmental delays
- Decision to breastfeed should consider clinical necessity and potential infant exposure
Children and Adolescents
- Approved for schizophrenia and bipolar mania in ages 13-17
- Higher risk of weight gain and metabolic effects than adults
- Long-term effects on growth and development not fully established
- Requires careful monitoring by pediatric psychiatrist
Elderly Patients
- Start with lower doses (2.5-5 mg)
- Greater chance of falling due to drowsiness and fluctuations in blood pressure.
- Higher risk of stroke and death in dementia (not approved for this use)
- More susceptible to anticholinergic side effects
Patients with Medical Conditions
| Condition | Consideration |
|---|---|
| Diabetes/prediabetes | Monitor closely; may worsen glucose control |
| High cholesterol/triglycerides | Regular lipid monitoring required |
| Heart disease | Risk of orthostatic hypotension, arrhythmias |
| Liver disease | May need dose adjustment |
| Seizure disorders | Lowered seizure threshold |
| Glaucoma | May worsen narrow-angle glaucoma |
| Enlarged prostate | Urinary retention risk |
| Intestinal blockage | Paralytic ileus risk |
Olanzapine Overdose Effects
Symptoms of Overdose
- Extreme drowsiness or sedation
- Slurred speech
- Rapid heartbeat
- Agitation or confusion
- Reduced breathing
- Loss of consciousness
- Seizures (rare)
Treatment
- No specific antidote exists
- Supportive care in emergency department
- Activated charcoal if early after ingestion
- Monitoring of vital signs and cardiac function
- Symptomatic treatment of complications
Stopping Olanzapine Safely
Never discontinue olanzapine abruptly without medical supervision. Potential withdrawal effects include:
- Insomnia or sleep disturbances
- Nausea and vomiting
- Anxiety or agitation
- Return of original symptoms (relapse)
- Movement disorders (rare)
Your doctor will typically reduce the dose gradually over weeks or months to minimize these effects.
Cost and Availability
- Generic available: Yes (significantly cheaper than brand name)
- Brand name Zyprexa: More expensive, may require prior authorization
- Insurance coverage: Generally covered by most prescription plans
- Patient assistance programs: Available through manufacturer for eligible uninsured patients
How Long Does Olanzapine Effect Last?
Olanzapine’s effects typically begin within a few hours after taking an oral dose, with peak concentrations in the bloodstream reached in about 5–8 hours.
The medication’s half-life—the time it takes for half of the drug to be eliminated from the body—is approximately 21–54 hours, meaning its effects can last for several days after a single dose.
For most people, the therapeutic effects (such as reduced symptoms of psychosis or mood stabilization) are sustained with daily dosing, but it may take 1–2 weeks of consistent use to notice significant improvement. T
he long-acting injectable form (Zyprexa Relprevv) releases the drug slowly over 2–4 weeks, providing extended symptom control. Always follow your doctor’s guidance regarding dosing and adjustments.
Timeline of Improvement
| Timeframe | Expected Effects |
|---|---|
| First few days | Sedation, some reduction in agitation |
| 1-2 weeks | Improvement in sleep, appetite; early reduction in anxiety |
| 2-4 weeks | Noticeable improvement in psychotic symptoms or mania |
| 4-6 weeks | Full therapeutic effect for acute symptoms |
| 3-6 months | Optimal mood stabilization; metabolic effects fully apparent |
Success Rates
- Approximately 60-70% of patients with schizophrenia show significant symptom improvement
- Response rates for acute mania are around 50-60%
- Many patients require long-term treatment to prevent relapse
Olanzapine Comparison with Similar Medications
| Feature | Olanzapine | Risperidone | Quetiapine | Aripiprazole |
|---|---|---|---|---|
| Sedation | High | Moderate | High | Low |
| Weight gain | High | Moderate | Moderate | Low |
| Metabolic effects | High | Moderate | Moderate | Low |
| Movement disorders | Low | Moderate | Very low | Very low |
| Prolactin elevation | Minimal | High | Minimal | Minimal |
| Cost (generic) | Low | Low | Low | Moderate |
Frequently Asked Questions About Olanzapine
Will I need to take olanzapine forever?
A: Many people take it long-term to prevent relapse, but duration depends on your condition, number of episodes, and response to treatment. Some may eventually taper off under medical supervision.
Can I lose the weight I gained?
A: Weight loss is challenging but possible through diet, exercise, and sometimes switching to a weight-neutral alternative. Metformin may help some patients lose weight gained from antipsychotics.
Does olanzapine change my personality?
A: No—it reduces symptoms of illness but doesn’t change your fundamental personality. Some people feel “flattened” emotionally, which can often be addressed by dose adjustment.
Is it addictive?
A: Olanzapine is not considered addictive in the traditional sense, but stopping suddenly can cause withdrawal symptoms and relapse of your condition.
Can I drink coffee or smoke?
A: Caffeine is generally fine in moderation. However, smoking significantly reduces olanzapine levels—tell your doctor if you start or stop smoking, as your dose may need adjustment.
When to Contact Your Doctor
Contact your healthcare provider immediately if you experience:
- Signs of high blood sugar (excessive thirst, frequent urination, unexplained weight loss)
- Uncontrolled movements of your face, tongue, or limbs
- Fever, stiff muscles, confusion, or irregular heartbeat
- Fainting or severe dizziness
- Thoughts of harming yourself
- Severe constipation lasting more than a few days
- Yellowing of skin or eyes
- Unusual bleeding or bruising
Sources & References
- Citrome, L. (2009) ‘Olanzapine: review of safety 2008’, Expert Opinion on Drug Safety, 8(3), pp. 479–489.
- Eli Lilly and Company (2024) Zyprexa (olanzapine) tablets: prescribing information. Indianapolis, IN: Eli Lilly and Company.
- Kane, J.M. et al. (2007) ‘Long-term efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a 4-year prospective follow-up’, Schizophrenia Research, 89(1-3), pp. 274–275.
- Keck, P.E. et al. (2003) ‘A placebo-controlled, randomized, double-blind study of adjunctive olanzapine for cocaine dependence’, Biological Psychiatry, 54(3), pp. 267–273.
- Leucht, S. et al. (2013) ‘Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis’, The Lancet, 382(9896), pp. 951–962.
- McElroy, S.L. et al. (2005) ‘A randomized, double-blind, placebo-controlled study of olanzapine in the treatment of binge-eating disorder’, Journal of Clinical Psychiatry, 66(4), pp. 447–453.
- National Alliance for Health Information Technology (2023) Olanzapine. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
- Tohen, M. et al. (2003) ‘Olanzapine versus placebo in the treatment of bipolar disorder: a double-blind, randomized study’, American Journal of Psychiatry, 160(12), pp. 2106–2117.
- World Health Organization (2021) Anatomical Therapeutic Chemical (ATC) classification system: N05AH03 – olanzapine. Geneva: World Health Organization.
- Yatham, L.N. et al. (2018) ‘Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder’, Bipolar Disorders, 20(2), pp. 97–170.